Shire PLC (ADR)  

(Public, NASDAQ:SHPG)   Watch this stock  
Find more results for NASDAQ:SHPGY
174.80
+3.82 (2.23%)
Dec 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 173.05 - 175.50
52 week 147.60 - 210.33
Open 174.50
Vol / Avg. 981,459.00/1.56M
Mkt cap 51.51B
P/E 65.78
Div/yield 0.14/0.46
EPS 2.66
Shares 910.90M
Beta 1.47
Inst. own 8%
Feb 13, 2017
Full Year 2016 Shire PLC Earnings Release (Estimated) Add to calendar
Nov 10, 2016
Shire PLC Investor Day
Nov 1, 2016
Q3 2016 Shire PLC Earnings Call
Nov 1, 2016
Q3 2016 Shire PLC Earnings Release
Sep 28, 2016
Shire PLC at Leerink Partners Rare Disease & IO Roundtable Series - Webcast
Sep 16, 2016
Shire PLC at Bank of America Merrill Lynch Healthcare Conference
Sep 12, 2016
Shire PLC at Morgan Stanley Global Healthcare Conference
Sep 7, 2016
Shire PLC at Wells Fargo Securities Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -10.65% 20.88%
Operating margin -11.76% 22.12%
EBITD margin - 44.15%
Return on average assets -2.10% 8.86%
Return on average equity -4.96% 14.47%
Employees 5,548 -
CDP Score - 91 B

Address

Hampshire Intl Business Park, Chineham
BASINGSTOKE, RG24 8EP
United Kingdom - Map
+44-1256-894000 (Phone)
+44-1256-894708 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 58
Bio & Compensation  - Reuters
Jeffrey Poulton Chief Financial Officer, Executive Director
Age: 48
Bio & Compensation  - Reuters
Ginger Gregory Chief Human Resource Officer
Bio & Compensation  - Reuters
William Mordan General Counsel, Company Secretary
Bio & Compensation  - Reuters
Phil J. Vickers Head of Research and Development
Age: 56
Bio & Compensation  - Reuters
Susan Saltzbart Kilsby Non-Executive Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Olivier Bohuon Non-Executive Director
Age: 57
Bio & Compensation  - Reuters
Gail D. Fosler Non-Executive Director
Age: 68
Bio & Compensation  - Reuters
Sara Mathew Non-Executive Director
Age: 61
Bio & Compensation  - Reuters
Albert P. L. Stroucken Non-Executive Director
Age: 68
Bio & Compensation  - Reuters